Published in HPB (Oxford) on March 29, 2011
Cholangiocarcinoma. Lancet (2014) 4.52
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc (2015) 2.70
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
Evaluation of indeterminate biliary strictures. Nat Rev Gastroenterol Hepatol (2015) 1.46
Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc (2014) 1.21
Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr (2014) 1.18
Biliary strictures: diagnostic considerations and approach. Gastroenterol Rep (Oxf) (2014) 0.99
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) (2015) 0.96
Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology (2012) 0.93
Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf) (2014) 0.88
Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion (2014) 0.84
Liver transplantation for hilar cholangiocarcinoma. World J Gastroenterol (2013) 0.83
Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol (2015) 0.82
Role of endoscopic ultrasonography in the evaluation of extrahepatic cholangiocarcinoma. Endosc Ultrasound (2013) 0.81
Liver masses: a clinical, radiologic, and pathologic perspective. Clin Gastroenterol Hepatol (2013) 0.81
Role of endoscopic retrograde cholangiopancreatography in the management of benign biliary strictures: What's new? World J Gastrointest Endosc (2016) 0.79
Endoscopic ultrasonography in the evaluation of indeterminate biliary strictures. Clin Endosc (2012) 0.78
Percutaneous biliary drainage is oncologically inferior to endoscopic drainage: a propensity score matching analysis in resectable distal cholangiocarcinoma. J Gastroenterol (2015) 0.77
Perioperative Management of Hilar Cholangiocarcinoma. J Gastrointest Surg (2015) 0.77
IgG4-Associated Cholangitis Can Mimic Hilar Cholangiocarcinoma. Gut Liver (2015) 0.77
Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma. Am J Gastroenterol (2015) 0.76
Quality indicators for EUS. Am J Gastroenterol (2014) 0.76
Usefulness of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of hepatic, gallbladder and biliary tract Lesions. World J Gastrointest Oncol (2014) 0.76
Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg (2014) 0.76
Xanthogranulomatous Cholecystitis Mimicking Biliary Tract Cancer. ACG Case Rep J (2015) 0.75
Biliary strictures: endoscopic assessment and management. Frontline Gastroenterol (2017) 0.75
Advanced endoscopic imaging of indeterminate biliary strictures. World J Gastrointest Endosc (2015) 0.75
Development of a Risk Score to Predict Detection of Metastasized or Locally Advanced Perihilar Cholangiocarcinoma at Staging Laparoscopy. Ann Surg Oncol (2016) 0.75
Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures. World J Gastrointest Endosc (2015) 0.75
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut (2008) 3.65
Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg (1996) 2.54
Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol (2008) 2.44
Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg (1999) 2.24
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc (2006) 1.93
Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol (2004) 1.86
Aggressive surgical resection for cholangiocarcinoma. Arch Surg (1995) 1.80
EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol (2004) 1.47
Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma. World J Gastroenterol (2005) 1.46
Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43
Tumor seeding from percutaneous biliary catheters. Ann Surg (1989) 1.41
Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis (2004) 1.34
Endoscopic ultrasound and fine-needle aspiration of unexplained bile duct strictures. Am J Gastroenterol (2004) 1.32
Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis (2004) 1.20
Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol (2000) 1.15
Surgical treatment of abdominal wall tumor seeding after percutaneous transhepatic biliary drainage. Am J Surg (2007) 1.10
Needle track seeding of primary and secondary liver carcinoma after percutaneous liver biopsy. HPB Surg (1993) 1.03
An update on primary sclerosing cholangitis. Curr Opin Gastroenterol (2008) 1.00
Transabdominal seeding of hepatocellular carcinoma after fine-needle aspiration biopsy. J Clin Ultrasound (1993) 0.96
Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin N Am (2002) 0.95
Cholangiocarcinoma: is transplantation an option? For whom? J Hepatol (2007) 0.94
MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension. AJR Am J Roentgenol (2001) 0.92
Needle-track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut (2009) 0.80
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
caGrid: design and implementation of the core architecture of the cancer biomedical informatics grid. Bioinformatics (2006) 9.83
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology (2012) 2.74
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Life and death by death receptors. FASEB J (2009) 2.39
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant (2004) 1.87
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66
Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63
Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60
The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58
Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol (2010) 1.56
Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res (2002) 1.56
Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.54
Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52
"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51
Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology (2013) 1.50
Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol (2003) 1.50
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49
Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol (2013) 1.48
Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48
Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol (2002) 1.47
Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl (2004) 1.47
The emergence of a new discipline, hepatobiliary oncology. Hepatology (2008) 1.46
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45
Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem (2007) 1.43
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.43
Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43
Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol (2013) 1.43